Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Senior Management
Scientific Advisory Board
Corporate Governance
Programs
Xolatryp
Myocardial Ischemia and Arrhythmia Control
Stroke
Traumatic Brain Injury
Investors
Investor Welcome
Company Fact Sheet
ASX Announcements
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past General Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Welcome
Company Fact Sheet
ASX Announcements
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past General Meetings
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
24-Oct-2024
Quarterly Activities Report and Appendix 4C
23-Oct-2024
Supplementary NYR-BI03 Study Confirm Strong Cardioprotection
16-Oct-2024
NYR Completes Safety Studies Ahead of Phase I Clinical Trial
7-Oct-2024
Brain Injury Program GLP Studies Further Update 6
4-Oct-2024
Investor Presentation
1-Oct-2024
Drug Candidate Demonstrates Significant Cardioprotection
1-Oct-2024
Trading Halt
1-Oct-2024
Pause in Trading
30-Sep-2024
2024 Annual General Meeting Access Letter, Notice and Proxy
27-Sep-2024
Brain Injury Program GLP Studies Further Update 5
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
Next
